Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Dr. Dixit currently serves as President and CEO of Bionavigen, a biopharmaceutical company specializing in consulting and drug hunting for biologic, cell and gene therapy and small molecule drug development. He is also President and CSO of Regio Biosciences, an AstraZeneca Spinoff company. Dr. Dixit is an accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, and AstraZeneca. He was a key contributor to successful approval of biotherapeutics, including five biologics (including antibodies and immunotoxins) and four small molecule pharmaceuticals. He was honored in 2020 by the World ADC Forum with its most prestigious award of Long-Standing Contributor to ADCs.
Seminars
- Identifying which toxicities are reasonably predictable from animal or in vitro studies
- Discussing toxicities that are still difficult to understand and where things are “falling apart”
- Exploring what can be done to further enhance the understanding of ADC toxicities, including focusing on key toxicities such as ocular and lung regions
- How can multiple payloads overcome tumour heterogeneity, resistance, and enhance anti-tumour efficacy?
- Discussing the strategies to mitigate overlapping toxicities, optimise therapeutic windows, and balance increased potency with safety profiles through development
- Examining how preclinical models, biomarker strategies, and translational approaches can better predict clinical outcomes and support the successful development of advanced ADC formats in the clinic
- Debating the optimal chemical and biological properties of next-generation payload and linker combinations
- Exploring the novelty of dual-payload ADCs and their potential to overcome resistance and improve safety profiles compared to traditional ADCs
- Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
